The Society for Immunotherapy of Cancer (SITC) hosted Session 208c during the 39th Annual Meeting & Pre-Conference Programs on Saturday, November 9, 2024. Available here are the presentation slides and video from “Session 208c: Evolution of Predictive Biomarkers in Immunotherapy: From Current State to Future Frontiers” as permitted by presenters.
Alessio Cortellini, MD, PhD – Fondazione Policlinico Campus Bio-Medico & Campus Bio-Medico University & Department of Surgery and Cancer, Imperial College London
Kerry L. Reynolds, MD – Massachusetts General Hospital
This session will provide a comprehensive overview of the evolving role of predictive biomarkers in immunotherapy, focusing on both current advancements and future directions. The discussion will begin with an exploration of the integration of predictive biomarkers in immuno-oncology, covering the latest state-of-the-art developments and their clinical implications. Following this, the session will delve into the use of novel omics biomarkers to enhance patient selection, including insights into cutting-edge techniques such as spatial transcriptomics. The session will also address the critical issue of biomarkers for immune-related adverse events, examining their current state and the potential impplications for clinical practice. Finally, the session will explore how model systems in drug development can drive advancements in immunotherapy. Through these discussions, attendees will gain a deeper understanding of the dynamic landscape of predictive biomarkers in immunotherapy, equipping them with the knowledge to address current challenges and seize future opportunities.
To view the entire program schedule (including presenter permission to post) please click here.
01:26:02